Buparlisib

Drug Profile

Buparlisib

Alternative Names: BKM-120; BKM120-AAA; Buparlisib hydrochloride; NVP-BKM120

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis; University Hospital Tubingen
  • Developer Array BioPharma; Dana-Farber Cancer Institute; Duke University Medical Center; Emory University; Indiana University; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (Canada); National Cancer Institute (USA); Novartis; Novartis Oncology; Ohio State University; Paoli-Calmettes-institute; Sarah Cannon Research Institute; Stanford University; University Hospital Tubingen; University of California at San Francisco
  • Class Amines; Antineoplastics; Morpholines; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma
  • Phase I B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Leukaemia; Mantle-cell lymphoma
  • Discontinued Basal cell cancer; Breast cancer; CNS cancer; Endometrial cancer; Gastrointestinal stromal tumours; Glioblastoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Thymoma

Most Recent Events

  • 21 Jul 2017 Novartis completes a phase II trial in Non-Hodgkin's lymphoma (Second-line therapy or greater) in US, Belgium, France, Germany, Spain, South Korea, Turkey and Italy (NCT01693614)
  • 17 May 2017 Novartis completes a phase I trial for Glioblastoma (Combination therapy, Newly diagnosed) in USA, Australia, Spain and Canada (PO) (NCT01473901)
  • 16 Mar 2017 Novartis Pharmaceuticals terminates a phase II trial in Oesophageal cancer in Japan (PO) (UMIN000011217)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top